Vaccines - Southern Asia | Statista Market Forecast

The Vaccines market in Southern Asia is expected to witness a substantial growth in revenue, reaching a projected value of US$2.72bn by 2025.
Furthermore, it is anticipated to maintain a steady growth rate with a compound annual growth rate (CAGR) of -3.70% from 2025 to 2029, leading to a market volume of US$2.34bn by the end of 2029.
When it comes to global comparison, United States is expected to generate the highest revenue in the Vaccines market, with a staggering US$29.97bn by 2025.
The demand for vaccines in Southern Asia has surged due to the increasing population and the government's push for immunization programs.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Vaccines against infectious diseases
Prophylactic and therapeutic vaccines
Flu vaccines
COVID-19 vaccines

Sera and gammaglobulins
Antivirals
Antibiotics

Vaccines: market data & analysis

The demand for vaccines in Southern Asia has been increasing steadily over the years.

Customer preferences: Customers in Southern Asia are increasingly aware of the importance of vaccination and are willing to invest in preventive healthcare measures. The rise in awareness can be attributed to the growing education and literacy rates, as well as the efforts of healthcare organizations and governments to promote vaccination.

Trends in the market: The vaccines market in Southern Asia is witnessing a shift towards combination vaccines, which offer protection against multiple diseases in a single shot. This trend is driven by the convenience it offers to patients and the cost savings it provides. Additionally, there is an increasing demand for vaccines that cater to specific age groups, such as elderly or pediatric vaccines. This trend is driven by the growing population of elderly individuals and the need for preventive healthcare for children.

Local special circumstances: Southern Asia is a diverse region with varying healthcare needs and challenges. Countries like India and Pakistan have a large population that is susceptible to infectious diseases, which drives the demand for vaccines. On the other hand, countries like Sri Lanka and Maldives have a relatively low prevalence of infectious diseases, which leads to a lower demand for vaccines. Additionally, the healthcare infrastructure in Southern Asia is not uniform, with some countries having better healthcare facilities than others.

Underlying macroeconomic factors: The economic growth in Southern Asia has led to an increase in disposable income, which has led to a higher demand for healthcare services, including vaccines. Additionally, the growing population in the region has led to an increase in demand for vaccines. Governments in the region have also been taking steps to improve healthcare infrastructure and promote preventive healthcare, which has further boosted the demand for vaccines. However, the high cost of vaccines and the lack of access to healthcare facilities in some areas remain a challenge for the growth of the vaccines market in Southern Asia.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.

Vaccines - Southern Asia

Revenue

Analyst Opinion

Global Comparison

Methodology

Health

Access more Market Insights on Health topics with our featured report

Key Market Indicators

Explore more high-quality data on related topic

Coronavirus (COVID-19): vaccines and vaccination campaign

Contact